Cargando…
Latest evidence on immunotherapy for cholangiocarcinoma
Cholangiocarcinoma (CCA) is a type of aggressive tumor that involves the intrahepatic, perihilar and distal biliary tree, and is usually diagnosed at an advanced stage. The standard first-line systemic therapy for patients with advanced CCA is a combination of gemcitabine and cisplatin; targeted the...
Autores principales: | Guo, Xurui, Shen, Weizhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608025/ https://www.ncbi.nlm.nih.gov/pubmed/33154779 http://dx.doi.org/10.3892/ol.2020.12244 |
Ejemplares similares
-
Cholangiocarcinoma in the Era of Immunotherapy
por: Manthopoulou, Eleni, et al.
Publicado: (2023) -
Latest developments in MUC1 immunotherapy
por: Taylor-Papadimitriou, Joyce, et al.
Publicado: (2018) -
Advances in cancer immunotherapy 2019 – latest trends
por: Kruger, Stephan, et al.
Publicado: (2019) -
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
por: Santoni, Matteo, et al.
Publicado: (2018) -
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021)